﻿<?xml version="1.0" encoding="UTF-8" ?>
<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
<channel rdf:about="http://medrxiv.org">
<admin:errorReportsTo rdf:resource="mailto:medrxiv@cshlpress.edu"/>
<title>medrxiv Subject Collection: Pain Medicine Palliative Medicine</title>
<link>http://medrxiv.org</link>
<description>
This feed contains articles for medRxiv Subject Collection "Pain Medicine Palliative Medicine"
</description>

<items>
<rdf:Seq>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.06.26347723v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.06.26347785v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.03.02.26347430v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.25.26346957v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.20.26346691v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.24.26346973v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.16.26346388v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.11.26346011v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.09.26345929v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.03.26345518v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.03.26345473v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.02.26345387v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.02.01.26345327v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.23.26344608v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.23.26344689v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.23.26344711v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.21.26344503v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.16.26344114v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.14.26344090v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.08.26343598v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.06.26343556v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.03.26343375v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.02.26343333v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2026.01.02.26343350v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.31.25343260v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.24.25342351v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.11.25341892v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.11.25342089v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.04.25341572v1?rss=1"/>
<rdf:li rdf:resource="https://www.medrxiv.org/content/10.64898/2025.12.05.25341696v1?rss=1"/>
</rdf:Seq>
</items>
<prism:eIssn/>
<prism:publicationName>medrxiv</prism:publicationName>
<prism:issn/>

<image rdf:resource=""/>
</channel>
<image rdf:about="">
<title>medrxiv</title>
<url>https://www.medrxiv.org/sites/default/files/medrxiv_internal_logo.png</url>
<link>http://medrxiv.org</link>
</image>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.06.26347723v1?rss=1">
<title>
<![CDATA[
Initiation of buprenorphine as part of pain management approach to trauma patients in the intensive care unit with a history of opioid use disorder: A QI Study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.06.26347723v1?rss=1
</link>
<description><![CDATA[
BackgroundBuprenorphine use in the intensive care unit (ICU) remains not well studied despite growing perioperative guidance supporting its continuation and initiation for patients with opioid use disorder (OUD). Trauma ICU admissions represent a critical opportunity to address untreated OUD, as well as continuation of an already established treatment plan for OUD, yet barriers limit its adoption in this setting.

MethodsThis single-center quality improvement study evaluated for inpatient buprenorphine prescribing patterns following provider education at a tertiary academic trauma center. Adult trauma ICU patients with OUD admitted between 2016-2024 were identified through the institutional trauma registry. Patients with pre-admission buprenorphine were excluded, yielding a cohort of 95 patients: 24 buprenorphine-exposed (initiated in the hospital) and 71 controls. Primary outcomes included pain scores and opioid requirements (morphine milligram equivalents, MME) during the first 48 hours. Secondary outcomes included hospital length of stay (LOS), discharge disposition, and 90-day readmission.

ResultsBaseline characteristics were similar between groups. No statistically significant differences were observed in first recorded pain scores (median 8 vs. 10; p=0.35), mean 48-hour pain scores (7.40 vs. 7.76; p=0.44), or total opioid consumption (232 vs. 119 mg MME; p=0.45). Median hospital LOS (16 vs. 19 days; p=0.48) and 90-day readmission rates (42.3% vs. 33.3%; p=0.40) were also comparable.

ConclusionInpatient buprenorphine initiation in trauma ICU patients with OUD was not associated with worse pain control, increased opioid requirements, or adverse clinical outcomes. These findings support the integration of buprenorphine into critical care pathways as a safe strategy to address OUD during hospitalization and improve long-term recovery continuity.
]]></description>
<dc:creator><![CDATA[ Khan, A., Rosario-Rivera, B. L., Shivanekar, S. P., Sperry, J. L., Emerick, T. D., Kaynar, A. M. ]]></dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.06.26347723</dc:identifier>
<dc:title><![CDATA[Initiation of buprenorphine as part of pain management approach to trauma patients in the intensive care unit with a history of opioid use disorder: A QI Study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.06.26347785v1?rss=1">
<title>
<![CDATA[
Exploring Electroencephalography for Chronic Pain Biomarkers: A Large-Scale Benchmark of Data- and Hypothesis-Driven Models 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.06.26347785v1?rss=1
</link>
<description><![CDATA[
Resting-state electroencephalography (EEG) has been proposed as a scalable source of biomarkers for chronic pain, but its clinical potential remains uncertain. To systematically evaluate this potential, we benchmarked nine modeling strategies, spanning conventional machine learning with handcrafted features to state-of-the-art deep learning. Across 72 configurations of signal representations and model architectures, we trained models to predict self-reported pain intensity, using chronological age decoding as a positive control. Pain prediction performance was limited (R=0.15), with the best results achieved by conventional connectivity-based models. In contrast, age was robustly decoded from the same dataset (R=0.53), confirming technical efficacy. These findings indicate that resting-state EEG contains limited information about inter-individual differences in chronic pain intensity, making it unlikely to yield clinically actionable biomarkers in cross-sectional settings. Instead, its potential may lie in intra-individual modeling of pain dynamics, which could advance individualized mechanistic insights and more personalized treatment of chronic pain.
]]></description>
<dc:creator><![CDATA[ Bott, F. S., Turgut, O., Zebhauser, P. T., Adhia, D. B., Ashar, Y. K., Day, M. A., Granovsky, Y., Jensen, M. P., Wager, T. D., Yarnitsky, D., Rueckert, D., Ploner, M. ]]></dc:creator>
<dc:date>2026-03-06</dc:date>
<dc:identifier>doi:10.64898/2026.03.06.26347785</dc:identifier>
<dc:title><![CDATA[Exploring Electroencephalography for Chronic Pain Biomarkers: A Large-Scale Benchmark of Data- and Hypothesis-Driven Models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-06</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.02.26347430v1?rss=1">
<title>
<![CDATA[
Personalizing neuromodulation for chronic pain: A connectivity-guided trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.02.26347430v1?rss=1
</link>
<description><![CDATA[
In this randomized, double-blind, controlled trial of 8 weeks of repetitive transcranial magnetic stimulation (rTMS) for chronic pain, we compared the classic primary motor cortex (M1) rTMS with a novel target-selection strategy based on pre-therapy cortical connectivity. Guided by principles of homeostatic plasticity, we tested whether stimulating the cortical site with the lowest pre-therapy global connectivity would be more effective than two active comparators: stimulating the site with the highest pre-therapy global connectivity or stimulating M1 independent of connectivity. Before starting rTMS treatment, TMS-evoked EEG potentials were recorded from four cortical targets: M1, the dorsolateral prefrontal cortex, the anterior cingulate cortex, and the posterosuperior insular cortex. For each target, global connectivity was quantified using a distance-weighted, phase-based index (debiased weighted phase lag index, wPLI) derived from pre- and post-TMS-evoked EEG activity, capturing both the magnitude and spatial extent of TMS-induced oscillatory phase locking across cortical regions. Target allocation in the Low- and High-Connectivity groups was based on this global connectivity measure. Ninety patients with chronic pain were randomized to Low-Connectivity, High-Connectivity, or Classic-M1 groups. Treatment consisted of 12 rTMS sessions delivered over 8 weeks to the assigned target. The primary outcome was the proportion of patients achieving [&ge;] 30% reduction in pain intensity. Secondary outcomes included continuous change in pain intensity, pain interference, sleep, fatigue, mood, quality of life, and patient global impression of change. No between-group differences were observed for primary or secondary outcomes (p > 0.05). In prespecified exploratory analyses, we examined whether pre-therapy local connectivity (within-target wPLI) predicted treatment response. In the Classic-M1 group, lower pre-therapy local M1 connectivity was associated with a greater reduction in pain intensity (r = 0.50, p = 0.005). This association was not observed in the Low- or High-Connectivity groups. A regression model including group-by-connectivity interaction indicated that the relationship between local connectivity and pain reduction differed between the Classic-M1 and High-Connectivity groups (p = 0.038). The results of this clinical trial showed that connectivity-based target allocation using global connectivity did not improve clinical outcomes. However, lower local M1 connectivity was associated with greater pain reduction following Classic-M1 stimulation, suggesting that local M1 connectivity may serve as a potential biomarker of response.
]]></description>
<dc:creator><![CDATA[ De Martino, E., Bach, M. M., Couto, B. N., Jakobsen, A., Martins, P. N., Ingemann-Molden, S., Casali, A. G., Graven-Nielsen, T., Ciampi de Andrade, D. ]]></dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.02.26347430</dc:identifier>
<dc:title><![CDATA[Personalizing neuromodulation for chronic pain: A connectivity-guided trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.25.26346957v1?rss=1">
<title>
<![CDATA[
Real-world Opioid-Sparring Effects of Infiltration between the Popliteal Artery and the Capsule of the Knee (IPACK) in Patients Undergoing Anterior Cruciate Ligament Reconstruction 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.25.26346957v1?rss=1
</link>
<description><![CDATA[
IntroductionPatients undergoing anterior cruciate ligament (ACL) reconstruction experience substantial postoperative pain, which delays recovery and leads to both immediate and long-term opioid use. In other knee procedures, infiltration between the popliteal artery and the capsule of the posterior knee (IPACK) has demonstrated analgesic and opioid reducing effects. However, the effect in patients undergoing ACL reconstruction has not been investigated. We aimed to investigate the real-world effect of IPACK in patients undergoing ACL reconstruction on immediate postoperative opioid consumption.

ParticipantsIn this single-centre difference-in-differences cohort study, all patients who underwent ACL reconstruction surgery at Bispebjerg Hospital, Denmark, from 1 February 2024 to 30 June 2025 are included. The study further includes a similar reference cohort, comprising all patients who underwent trochleaplasty, Elmslie-Trillat, or medial patellofemoral ligament reconstruction during the same period, and at the same hospital.

InterventionThe primary exposure is the implementation of IPACK as part of perioperative management for ACL reconstruction on 1 January 2025. The IPACK was performed under ultrasound guidance, immediately before surgery, administering 20 mL of ropivacaine 0.5% between the popliteal artery and the posterior knee capsule.

OutcomesThe primary outcome is the cumulative opioid consumption from surgical incision to 2 hours postoperatively. Secondary outcomes include the cumulative opioid consumption from incision to 24 hours postoperatively, the worst reported pain score at 0-24h postoperatively, occurrence of postoperative nausea or vomiting (PONV) 0-24h postoperatively, length of PACU stay, length of hospital stay, and nerve injuries. As an exploratory outcome, carbon dioxide emissions will be investigated.

Statistical analysisThe main analysis will be a standard two-way fixed effects DiD regression assessing the changes occurring at the time of implementation of IPACK in the ACL cohort, with adjustment for the underlying time trend. Continuous outcomes are reported as mean difference (95% confidence interval [CI]), and binary outcomes as absolute and relative risks (95% CI).
]]></description>
<dc:creator><![CDATA[ Karlsen, A. P. H., Olsen, M. H., Barfod, K. W., Lunn, T. H., Bitsch, M. S., Wiberg, S. C., Laigaard, J. H. ]]></dc:creator>
<dc:date>2026-03-02</dc:date>
<dc:identifier>doi:10.64898/2026.02.25.26346957</dc:identifier>
<dc:title><![CDATA[Real-world Opioid-Sparring Effects of Infiltration between the Popliteal Artery and the Capsule of the Knee (IPACK) in Patients Undergoing Anterior Cruciate Ligament Reconstruction]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-03-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.20.26346691v1?rss=1">
<title>
<![CDATA[
Spinal Cord Stimulation for Persistent Spinal Pain Syndrome Type II: A Systematic Review and Subgroup Meta-analysis of Randomized Controlled Trials 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.20.26346691v1?rss=1
</link>
<description><![CDATA[
BackgroundPersistent Spinal Pain Syndrome (PSPS) type II represents a challenging clinical entity with limited therapeutic options. Various spinal cord stimulation (SCS) modalities have emerged as potential treatments, but their comparative effectiveness remains unclear.

ObjectiveOur goal in this paper is to systematically evaluate and compare the efficacy of different SCS modalities in patients with PSPS type II through meta-analysis of available randomized controlled trials.

Evidence ReviewWe conducted a systematic review following PRISMA guidelines, searching major databases for randomized controlled trials evaluating SCS modalities in PSPS type II patients until the end of May 2025(search updated on October 3rd). Primary outcomes included pain intensity (VAS) and functional disability (ODI) at 6 and 12 months. Subgroup analyses compared tonic versus burst stimulation and high-frequency versus low-frequency SCS.

FindingsNine randomized controlled trials were included, encompassing 565 patients across different SCS modalities. For the primary outcome of clinically meaningful pain relief ([&ge;]50% reduction), pooled analysis demonstrated that 45% (95% CI: 18-75%, I{superscript 2} = 92.2%) of patients achieved this threshold for back pain and 55% (95% CI: 45-65%, I{superscript 2} = 0%) for leg pain. Subgroup analysis revealed significant differences in back pain responder rates by stimulation modality: High-frequency SCS demonstrated responder rates of 92% (95% CI: 79-98%) versus 28% (95% CI: 13-49%) for conventional frequencies (p < 0.001). For leg pain, no significant difference was observed between tonic (51%, 95% CI: 37-65%) and burst stimulation (60%, 95% CI: 45-74%, p = 0.36) and mean VAS scores demonstrated significantly lower pain with high-frequency SCS (13.30, 95% CI: 8.82-17.78) compared to conventional frequency (28.42, 95% CI: 24.02-32.88, p<0.0001). For back pain, mean VAS scores decreased from a baseline of 73.03 to 41.67 (95% CI: 36.12-47.22, I{superscript 2}=22.8%) at 6 months and remained stable at 35.66 (95% CI: 25.39-45.93, I{superscript 2}=75.0%) at 12 months. Leg pain showed more pronounced improvement, with VAS scores declining from a baseline of 61.81 to 23.75 (95% CI: 17.69-29.81, I{superscript 2}=78.8%) at 6 months and 29.16 (95% CI: 24.81-33.52, I{superscript 2}=0%) at 12 months). Meta-regression identified longer pain duration and older age as positive predictors of response, while higher baseline leg pain predicted lower responder rates. Serious adverse events occurred in 10%, with a 16% revision surgery rate. Only two studies demonstrated a low risk of bias across all domains.

ConclusionsCurrent evidence demonstrates that various SCS modalities provide clinically meaningful pain relief in PSPS type II patients, with approximately half achieving [&ge;]50% pain reduction. High-frequency SCS shows significantly superior responder rates for back pain compared to conventional tonic stimulation, while burst stimulation yields significantly superior reductions in continuous pain intensity metrics. However, the limited number of studies, substantial heterogeneity, and lack of head-to-head comparisons prevent definitive recommendations regarding optimal stimulation parameters. Future large-scale randomized trials with standardized protocols and responder-based outcomes are needed to establish evidence-based treatment algorithms for PSPS type II patients.
]]></description>
<dc:creator><![CDATA[ Delbari, P., Pourahmad, R., Zare, A. h., Sabet, S., Ahmadvand, M. H., rasouli, K., Jakobs, M. ]]></dc:creator>
<dc:date>2026-02-26</dc:date>
<dc:identifier>doi:10.64898/2026.02.20.26346691</dc:identifier>
<dc:title><![CDATA[Spinal Cord Stimulation for Persistent Spinal Pain Syndrome Type II: A Systematic Review and Subgroup Meta-analysis of Randomized Controlled Trials]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.24.26346973v1?rss=1">
<title>
<![CDATA[
Study protocol for microneurographic investigation of nociceptor sensitisation in Fibromyalgia Syndrome. (MICRO-FMS) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.24.26346973v1?rss=1
</link>
<description><![CDATA[
IntroductionChronic pain in fibromyalgia may be driven by abnormal ongoing activity in a subclass of C-fibre nociceptors known as Type1B or CMi nociceptors. As is common in C-nociceptor microneurography studies, the modest patient numbers in these prior studies generate large confidence intervals around the point estimate of the prevalence of this abnormal activity. This complicates the interpretation of the relative importance of this ongoing nociceptor activity as a pain generating mechanism in fibromyalgia. The study aims to improve precision via an adaptive Bayesian protocol that maximises the yield and quality of data collection whilst minimising patient burden.

MethodsThe study employs an optimised microneurography protocol with an adaptive study design. The microneurography protocol incorporates early identification of CMi nociceptors via an abbreviated activity dependent slowing protocol to increase yields enabling efficient collection of the primary outcome data. The adaptive study design will use Bayesian principles to iteratively assess the predictive probability of futility, and terminate early if there is high confidence that the hypothesis is false. Furthermore, the study will employ questionnaires to explore links with pain in the area under study to the electrophysiology data. Finally, quantitative sensory testing will be used to investigate whether the irritable nociceptor phenotype is associated with abnormalities in CMi nociceptor physiology.

Ethics & DisseminationThis study has received HRA REC approval in the UK. Participants will provide written informed consent, and may withdraw at any time without consequence. At the end of the study, the results will be disseminated through peer-reviewed publication, and the data made available via a data repository.

Strengths & limitations of this studyBayesian predictive probability of futility to minimise patient burden in microneurography
Microneurography for objective interrogation of the peripheral nervous system
Optimised microneurography protocol to efficiently answer primary hypotheses
Subjective elements of early termination criteria of the study assessed and co-developed with Patient and Public Inclusion and Engagement Group
]]></description>
<dc:creator><![CDATA[ Ajay, E. A., Khan, F., Bhattacharjee, A., Pickering, A. E., Dunham, J. P. ]]></dc:creator>
<dc:date>2026-02-26</dc:date>
<dc:identifier>doi:10.64898/2026.02.24.26346973</dc:identifier>
<dc:title><![CDATA[Study protocol for microneurographic investigation of nociceptor sensitisation in Fibromyalgia Syndrome. (MICRO-FMS)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-26</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346388v1?rss=1">
<title>
<![CDATA[
Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346388v1?rss=1
</link>
<description><![CDATA[
New-onset chronic pain is a common and debilitating symptom of Long COVID (LC) that remains not fully understood in terms of pathophysiology and therapeutic targets. A growing body of evidence in chronic pain syndromes similar to LC demonstrates an association between EEG alpha oscillatory activity and the experience of pain, with clinical studies showing maladaptive changes in oscillatory activity, particularly a slowing of alpha activity. This study aims to investigate the association between EEG alpha oscillatory activity and pain perception in new-onset LC-chronic pain. We recruited 31 individuals (20 females) with a clinical diagnosis of LC reporting new-onset chronic pain and 31 healthy pain-free age-and sex-matched controls. Participants completed questionnaires regarding symptoms and psychological functioning prior to recording eyes-open resting-state EEG. Peak alpha frequency (PAF) and spectral power within the alpha band (8-13 Hz) were extracted from EEG signals. Lower PAF over the posterior scalp region was significantly associated with higher LC-chronic pain severity when controlling for age and depression. This observation was consistent across PAF estimation methods. PAF was significantly increased, particularly in the posterior region, in the moderate pain LC subgroup compared to both severe pain subgroup and controls, while alpha power did not differ between the three groups and was not associated with pain severity. Our findings highlight associations between PAF and pain symptoms in a new post-infection chronic pain syndrome. PAF can thus be explored as a potential biomarker and therapeutic target for EEG-based neuromodulation interventions in LC-chronic pain. These results may have implications for other similar chronic pain syndromes.

SummaryLower resting-state EEG peak alpha frequency in posterior scalp region is associated with higher severity of new-onset Long COVID chronic pain.
]]></description>
<dc:creator><![CDATA[ Silva-Passadouro, B., Khoja, O., Casson, A. J., Delis, I., Brown, C., Sivan, M. ]]></dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346388</dc:identifier>
<dc:title><![CDATA[Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.11.26346011v1?rss=1">
<title>
<![CDATA[
Evaluation of a Cook Islands Maori model of palliative care: a protocol 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.11.26346011v1?rss=1
</link>
<description><![CDATA[
AimThis research aims to evaluate the effectiveness, cultural appropriateness, and feasibility of the Cook Islands palliative care model te vaerua k[o]p[u] tangata ora within palliative care practice.

BackgroundAccess to palliative and end of life care is a recognised human right, yet significant disparities persist for Pacific peoples in Aotearoa, New Zealand. While the understanding of different cultural perspectives has grown, in Aotearoa, there remain gaps in the delivery of culturally appropriate palliative care.

MethodologyThis study will use a Cook Islands T[i]vaevae research methodology to guide semi-structured interviews with 25-35 Cook Islands community members and 10 palliative care clinicians. This approach will support a rich, relational, and culturally grounded exploration of how a Cook Islands M[a]ori palliative care model can be integrated into clinical practice.

DiscussionRecommendations to improve culturally responsive palliative care will be formulated in collaboration with community members and clinicians. The study will contribute to the limited body of knowledge on Pacific cultural understandings of palliative care and provide practical insights into applying an indigenous Pacific model within the palliative care system.
]]></description>
<dc:creator><![CDATA[ Henry, A., Tautolo, E.-S., Herman, J., Dewar, J., Maua-Hodges, T., Mulipola, I. ]]></dc:creator>
<dc:date>2026-02-14</dc:date>
<dc:identifier>doi:10.64898/2026.02.11.26346011</dc:identifier>
<dc:title><![CDATA[Evaluation of a Cook Islands Maori model of palliative care: a protocol]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-14</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.09.26345929v1?rss=1">
<title>
<![CDATA[
Development of a network for interactions and associations among biopsychosocial features of chronic low back pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.09.26345929v1?rss=1
</link>
<description><![CDATA[
BackgroundUnderstanding the associations among biopsychosocial factors is essential for improving research and treatment of chronic low back pain (CLBP). Here we characterized interrelations among biopsychosocial domains using network analysis and identified the most influential features in CLBP.

MethodsData came from Quebec Low Back Pain Study, comprising 4,489 CLBP participants. We modeled relationships among baseline biopsychosocial features as networks, where nodes represent features and edges encode statistical or causal dependencies among them. Undirected network was inferred using distance correlation. Directed network was constructed using the Linear Non-Gaussian Acyclic Model, which estimates plausible causal directions. Influence maximization was performed using the Independent Cascade (IC) model to identify the most influential features in each network.

ResultsIn the undirected network, physical function and pain interference were the most central nodes, followed by depression. In the directed network, fear of movement, catastrophizing, and widespread pain emerged as key downstream hubs receiving multiple causal inputs, whereas pain interference, physical function, and depression acted as major upstream drivers exerting broad causal influence. IC diffusion simulations further identified pain interference and physical function as the most influential features in the undirected and directed networks, respectively.

ConclusionsPain interference, physical function, and depression consistently emerged as key components of the CLBP biopsychosocial network. These features exert causal effects on fear of movement, catastrophizing, and widespread pain, with diffusion analyses confirming their roles as system-wide drivers. Interventions targeting functionality and pain interference, rather than pain intensity alone, may yield broader benefits across psychological and functional domains.
]]></description>
<dc:creator><![CDATA[ Rabiei, P., Masse-Alarie, H., Desrosiers, P. ]]></dc:creator>
<dc:date>2026-02-11</dc:date>
<dc:identifier>doi:10.64898/2026.02.09.26345929</dc:identifier>
<dc:title><![CDATA[Development of a network for interactions and associations among biopsychosocial features of chronic low back pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-11</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.03.26345518v1?rss=1">
<title>
<![CDATA[
PALLIATIVE CARE INTEGRATED INTO PRIMARY HEALTHCARE SERVICE (PALLI PHC) : AN IMPLEMENTATION STUDY IN ROHINGYA REFUGEE SETTING IN COXS BAZAR, BANGLADESH 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.03.26345518v1?rss=1
</link>
<description><![CDATA[
In humanitarian crises, health services focus on acute lifesaving care, and the needs of patients with chronic, progressive, and/or life-limiting illnesses are usually neglected. To address this gap, the International Organization for Migration (IOM) has been implementing an integrated palliative care service model: Palliative Care Integrated into Primary Healthcare (PALLI-PHC). This study aims to assess service outputs and patient-level outcomes of the model in the Rohingya refugee camps.

PALLI-PHC consists of a service delivery system supported by a health system support chain. The service is delivered at facility and home levels with an established referral pathway, triage and assessment, clinical evaluation, and care planning. The support chain comprises multidisciplinary engagement, health workforce, advocacy and capacity building, financing, community engagement, essential medical logistics, and information management.

Between January 2020 and December 2024, the programme delivered 40,776 consultations for a cohort of 11,599 patients. The top conditions managed were stroke, cancers, diabetic complications, hypertensive complications, and COPD. Prevalent symptoms included pain, fatigue, anxiety and worry, depressed mood, shortness of breath, and insomnia. Care was provided through facility-based and home-based services, including pain and symptom management, psychosocial and spiritual support, rehabilitation, caregiver support, and end-of-life care. Across follow-up visits, mean ESAS-r symptom scores declined significantly and the proportion receiving pain medication increased, although average disability scores also rose modestly over time.

This study shows how palliative care can be integrated into primary healthcare in a protracted humanitarian setting and can achieve measurable patient-level improvements, including reduced symptom burden and increased pain medication utilization.
]]></description>
<dc:creator><![CDATA[ Halder, C. E., Zaman, S. S. U., Hasan, M. A., Rahman, M. M., Sayum, M. A., Soma, E. R., Okello, J. C. ]]></dc:creator>
<dc:date>2026-02-05</dc:date>
<dc:identifier>doi:10.64898/2026.02.03.26345518</dc:identifier>
<dc:title><![CDATA[PALLIATIVE CARE INTEGRATED INTO PRIMARY HEALTHCARE SERVICE (PALLI PHC) : AN IMPLEMENTATION STUDY IN ROHINGYA REFUGEE SETTING IN COXS BAZAR, BANGLADESH]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-05</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.03.26345473v1?rss=1">
<title>
<![CDATA[
Using electronic health record data accessed via OpenSAFELY to develop indicators of end-of-life care quality 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.03.26345473v1?rss=1
</link>
<description><![CDATA[
An understated disruption to health services brought about by the Covid-19 pandemic was the increase in deaths occurring outside a hospital. Since quality of end-of-life care is typically monitored through place of death and hospital activity, a new approach focused on care in community settings is needed. In this study, we aimed to test whether patient-centric measures of quality at the end of life can be derived from primary care electronic records.

With the approval of NHS England, analysis was undertaken in OpenSAFELY-TPP using electronic health care records of over 970,000 patients who died between March 2019 and August 2023, covering periods before, during and after the pandemic. We developed two new measures of end-of-life care quality--specialist palliative care team contacts and advance care planning, and tracked the proportion of patients with these records, categorized by place and cause of death, along with an existing measure indicating palliative care needs.

The proportion of people with a GP record of specialist palliative care was 4-5% on average, higher for those who died of cancer or died in a hospice. Advance care planning records increased from 19% to 27% (barring a decrease following the onset of the Covid-19 pandemic) driven in large part by increases for patients who died in care homes. Advance care planning and recording of palliative care needs were plausible measures to track changes in care, unlike the specialist palliative care measure where recorded use was sparse. Improved coding in primary care records would improve reliability of measures.

Key messagesO_LIQuality of end-of-life care is traditionally measured by how patients use health services (for example emergency department attendances)
C_LIO_LIWe used routine GP health records to track aspects of end-of-life care quality which matter to patients and discuss the impact of the covid-19 pandemic on these quality measures
C_LIO_LIA new measure of advance care planning and the existing palliative care needs measure could be used to track end of life care delivered in the community
C_LIO_LIThe measure of specialist palliative care was sparsely coded and unlikely to be useful unless coding and data linkage between GP and other systems improves
C_LI
]]></description>
<dc:creator><![CDATA[ Bagri, S., Julian, S., Davies, M., Scobie, S., Schaffer, A., Collaborative, T. O. ]]></dc:creator>
<dc:date>2026-02-04</dc:date>
<dc:identifier>doi:10.64898/2026.02.03.26345473</dc:identifier>
<dc:title><![CDATA[Using electronic health record data accessed via OpenSAFELY to develop indicators of end-of-life care quality]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.02.26345387v1?rss=1">
<title>
<![CDATA[
Fatigue Links Sociodemographic Risk to Pain Intensity and Spread in Two Surgical Cohorts 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.02.26345387v1?rss=1
</link>
<description><![CDATA[
Why some surgical participants experience pain that extends beyond the original site of injury while others do not remains poorly understood. Both pain intensity and widespread pain contribute to recovery and quality of life, yet their psychosocial correlates are often examined separately. Using data from two large pre-surgical cohorts--participants preparing for knee replacement or thoracic surgery--we examined associations between sociodemographic and psychosocial factors, pain intensity at surgical and non-surgical sites, and widespread chronic pain. Across cohorts and outcomes, fatigue showed the strongest and most consistent associations with pain intensity and widespread pain, independent of other measured factors. Fatigue also occupied a central position in statistical association networks and accounted for substantial shared variance among multiple psychosocial variables, including sleep disturbance, depression, stress, and socioeconomic disadvantage. Pain at non-surgical sites was strongly associated with widespread pain and frequently accounted for observed associations between surgical-site pain and widespread pain. Together, these findings highlight robust patterns of association linking fatigue, pain intensity, and widespread pain in pre-surgical populations.

One Sentence SummaryFatigue is the strongest and most consistent factor linked to how pain intensifies and spreads before surgery.
]]></description>
<dc:creator><![CDATA[ Sun, M., Ansari, B., Clauw, D., Harris, R. E., Sluka, K. A., Kaplan, C. M., Brummett, C. M., Lindquist, M. A., Wager, T. D., A2CPS Consortium ]]></dc:creator>
<dc:date>2026-02-04</dc:date>
<dc:identifier>doi:10.64898/2026.02.02.26345387</dc:identifier>
<dc:title><![CDATA[Fatigue Links Sociodemographic Risk to Pain Intensity and Spread in Two Surgical Cohorts]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.01.26345327v1?rss=1">
<title>
<![CDATA[
Developing Evidence-Based Criteria for Oxycodone Prescribing in Emergency Departments: A Protocol for the OxyGuidED Study Using the RAND/UCLA Appropriateness Method 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.01.26345327v1?rss=1
</link>
<description><![CDATA[
BackgroundOxycodone is widely prescribed for managing acute pain in emergency departments (ED), but the appropriateness of this prescription is not fully established. Although concerns about opioid misuse and dependence drive efforts to reduce inappropriate prescribing, there is increasing recognition of the importance of adequate pain management. Therefore, it is essential to develop appropriate prescribing criteria that balance the risks and benefits of opioids, ensuring their benefits are maximised while minimising potential harm.

ObjectiveFollowing the recommended format for a research protocol paper, this protocol describes the process and methods used to develop evidence-based criteria for oxycodone prescribing in the ED, informed by scientific evidence and expert clinical judgment, using the RAND/UCLA Appropriateness Method.

MethodThe process will be carried out in sequential stages. First, scope and key terms will be defined, and then a targeted literature review will be conducted to synthesise available evidence. Subsequently, based on this synthesis and the investigator teams clinical insights, clinical scenarios will be developed in collaboration with field experts. A multidisciplinary panel comprising specialists in emergency medicine, emergency nurses, and pharmacists will evaluate these scenarios in two rounds. Each scenario will be rated on a 1-9 scale, where 1 indicates that harm outweighs benefit and 9 indicates that benefit outweighs harm. The median rating score will fall between 1 and 9, where 1-3 without disagreement is inappropriate, 4-6 without disagreement is uncertain, and 7-9 without disagreement is appropriate. Disagreement is defined as at least three experts scoring in both extremes. Final scenario ratings will be presented according to their assessed appropriateness and used to inform appropriateness criteria for prescribing oxycodone in the adult ED.

ConclussionThe RAND/UCLA Appropriateness Method offers a systematic and evidence-informed framework for developing prescribing criteria to support the appropriate use of oxycodone in adult ED.
]]></description>
<dc:creator><![CDATA[ ALTHAGAFI, S. M., Keogh, S. M., Hughes, J. ]]></dc:creator>
<dc:date>2026-02-03</dc:date>
<dc:identifier>doi:10.64898/2026.02.01.26345327</dc:identifier>
<dc:title><![CDATA[Developing Evidence-Based Criteria for Oxycodone Prescribing in Emergency Departments: A Protocol for the OxyGuidED Study Using the RAND/UCLA Appropriateness Method]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-02-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.23.26344608v1?rss=1">
<title>
<![CDATA[
How does palliative care fit into national health spending? A secondary analysis of trends in long-term healthcare expenditure in the United Kingdom 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.23.26344608v1?rss=1
</link>
<description><![CDATA[
ObjectivesCurrent methods of health expenditure reporting make spending on palliative care services difficult to quantify. This paper (1) examines trends in the components of government (public) spending on health-related long-term care reported in the UK Health Accounts for the period of 2013 to 2022 to establish the wider context of palliative care expenditure, and (2) relates these trends to existing knowledge of expenditure on specialist palliative care services in the UK.

MethodsWe conducted a descriptive secondary analysis of annually reported government expenditure on health-related long-term care between 2013 and 2022 from the UK Health Accounts dataset. We contrasted this with UK governmental and non-governmental spending on specialist palliative care services using annual expenditure figures reported by Hospice UK.

ResultsReal-terms UK government spending on health-related long-term care grew by {pound}6.4 billion (22.9%) between 2013 and 2022, from {pound}27.9 to {pound}34.3 billion. Real-terms spending on specialist palliative care grew by {pound}110 million (10.7%) over the same period, from {pound}1,027 to {pound}1,137 million.

In 2022, spending on inpatient care comprised the majority of government health-related long-term care expenditure ({pound}22.6 billion; 65.9%). Home-based care comprised one-third ({pound}11.8 billion; 33.4%). Outpatient care accounted for 0.7% ({pound}260.2 million). Equivalent data was not available for analysis of specialist palliative care expenditure.

ConclusionsLow granularity of UK national health expenditure accounts limits national and international comparisons of spending on palliative care. However, it is clear that UK expenditure on specialist palliative care services has not kept pace with growth in expenditure on health-related long-term care.

What is already known on this topicO_LIGlobal demand for palliative care is increasing as rates of serious life-limiting illness, dementia, cancer and multiple long-term conditions rise internationally.
C_LIO_LIIncreasing complexity of illness and population ageing are two factors implicated in both rising healthcare expenditure and growing demand for palliative care internationally.
C_LIO_LIThe UK has previously been ranked as providing the highest quality of palliative care amongst international competitors - however, concerns about the longevity of funding sources for specialist palliative care services has led to calls for further investment.
C_LI

What this study addsO_LIReal terms UK government spending on health-related long-term care - which includes, but is not limited to, palliative care services - increased by 22.9% between 2013 and 2022.
C_LIO_LIOver the same period, UK spending on specialist palliative care services as reported by Hospice UK grew by only 10.7%.
C_LIO_LIOur results take into account health-related social care spending, which forms a key part of care for people living with illness, including those receiving palliative care services.
C_LI

How this study might affect research, practice or policyO_LIThe future of funding for specialist palliative care in the UK is uncertain, and current funding frameworks are complex. This paper adds to ongoing policy discussions surrounding this issue, highlighting the discrepancy between growth in public sector spending on health-related long-term care and overall spending on specialist palliative care services (from governmental and non-governmental sources).
C_LI
]]></description>
<dc:creator><![CDATA[ De-Alker, E., Alcock, A., Murtagh, F. E. ]]></dc:creator>
<dc:date>2026-01-24</dc:date>
<dc:identifier>doi:10.64898/2026.01.23.26344608</dc:identifier>
<dc:title><![CDATA[How does palliative care fit into national health spending? A secondary analysis of trends in long-term healthcare expenditure in the United Kingdom]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.23.26344689v1?rss=1">
<title>
<![CDATA[
Astrocytes in neuropathic pain: Mechanistic and global insights 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.23.26344689v1?rss=1
</link>
<description><![CDATA[
BackgroundNeuropathic pain (NP) is a debilitating chronic pain condition caused by injury or disease of the somatosensory nervous system. Accumulating evidence indicates that astrocytes play a central role in neuroinflammatory regulation and synaptic remodeling, thereby critically influencing the initiation and persistence of neuropathic pain. However, a comprehensive overview of research trends and knowledge structures in this field is still lacking.

MethodsThe analysis was conducted based on publications retrieved from the Web of Science Core Collection and Scopus, covering the period from 2000 to 2025. Studies focusing on astrocytes and neuropathic pain were systematically identified. Visualization and network analyses were performed using CiteSpace, VOSviewer, and the R package bibliometrix. Collaboration networks, co-citation patterns, keyword co-occurrence, and thematic evolution were analyzed to delineate research hotspots, developmental trajectories, and scholarly contributions across countries, institutions, authors, and journals.

Results1,828 publications were included, showing a 15% average annual growth in output, which accelerated post-2010. The USA and China led in research and international collaboration, with studies concentrated in North American and East Asian institutions. Author productivity was uneven, with key researchers (Ji RR, Zhang Y, Watkins LR) contributing heavily to publications and citations. Pain and Molecular Pain were the core journals. Key themes included spinal astrocytic mechanisms, glial activation, and therapeutic modulation, with the focus evolving from injury models/markers to astrocytic activation and targeted pathways.

ConclusionOur analysis shows a substantial growth in astrocyte-related NP research the past 25 years, underscoring astrocytes key role in chronic pain pathophysiology. Current trends underscore the integration of mechanistic insights with translational relevance, thereby informing future therapeutic and mechanistic advancements in NP.
]]></description>
<dc:creator><![CDATA[ Fan, H., Xue, L., Yuan, H., Yang, J., Yuan, Q. ]]></dc:creator>
<dc:date>2026-01-24</dc:date>
<dc:identifier>doi:10.64898/2026.01.23.26344689</dc:identifier>
<dc:title><![CDATA[Astrocytes in neuropathic pain: Mechanistic and global insights]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.23.26344711v1?rss=1">
<title>
<![CDATA[
Linking Data-Driven Symptom Dimensions to Resting-State EEG Biomarker Candidates in Chronic Pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.23.26344711v1?rss=1
</link>
<description><![CDATA[
Chronic pain (CP) is a multidimensional condition characterized by physical, emotional, and cognitive symptoms. However, many neuroimaging studies investigating the brain mechanisms of CP have focused on single-domain measures, most commonly pain intensity. Incorporating multidimensional symptom profiles may advance the understanding of CP, its neural underpinnings, and the development of clinically actionable biomarkers. Here, we aimed to empirically derive symptom dimensions of CP and relate them to resting-state brain activity and connectivity measured by electroencephalography (EEG). Using a data-driven approach, we identified latent symptom dimensions in 207 individuals with CP based on the brief, internationally validated PROMIS-29 profile, which assesses general health across key physical, mental, and social domains. Principal component analysis revealed two dimensions, affective burden and physical burden, closely corresponding to established PROMIS-derived health dimensions in other clinical populations. Resting-state EEG was obtained in a subsample of 116 participants using a mobile, rapid-to-deploy 29-channel dry-electrode system. Bayesian regression analyses provided moderate to strong evidence for a negative association between affective burden and beta-band connectivity, particularly in left frontal and somatomotor regions. Together, these findings demonstrate how empirically derived symptom dimensions captured by PROMIS-29 can be linked to scalable, network-level EEG biomarkers. This framework illustrates an EEG-informed strategy for biopsychosocial stratification in CP, with potential relevance for personalized symptom-targeted interventions.
]]></description>
<dc:creator><![CDATA[ Zebhauser, P. T., Bott, F. S., Baki, E., Heitmann, H., Bruna, N., May, E. S., Ploner, M. ]]></dc:creator>
<dc:date>2026-01-24</dc:date>
<dc:identifier>doi:10.64898/2026.01.23.26344711</dc:identifier>
<dc:title><![CDATA[Linking Data-Driven Symptom Dimensions to Resting-State EEG Biomarker Candidates in Chronic Pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-24</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.21.26344503v1?rss=1">
<title>
<![CDATA[
Chronic pain: transdiagnostic meta-analytic evidence of convergent network signature with PTSD 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.21.26344503v1?rss=1
</link>
<description><![CDATA[
Chronic pain is increasingly conceptualized within a stress-related framework. However, it remains unclear whether chronic pain and prototypical stress-related conditions--such as post-traumatic stress disorder (PTSD)--share common neurobiological substrates. To this end, we conducted a pre-registered transdiagnostic meta-analytic study of gray matter volume alterations in chronic pain (60 studies) and PTSD (20 studies). Disorder-specific meta-analyses revealed that chronic pain was associated with distributed volume reductions across ventromedial prefrontal, middle cingulate, and insular cortices, whereas PTSD exhibited a single cluster of reduced volume in the anterior cingulate/dorsomedial prefrontal cortices. A conjunction analysis revealed that both conditions converged onto an overlapping cluster of reduced volume in the bilateral medial orbitofrontal/anterior cingulate area. Using normative resting-state fMRI data (HCP 7T dataset), we found that chronic pain neuroanatomical abnormalities were embedded within a distributed architecture of large-scale circuits encompassing mesocorticolimbic/reward, default mode, salience, frontoparietal, dorsal attention, and somatosensory networks. On the other hand, the PTSD focal neuroanatomical alteration was embedded in a single large-scale circuit mapping onto the mesocorticolimbic/reward, default mode, salience, and visual networks. In both conditions, the mesocorticolimbic/reward circuit emerged as the most robustly involved large-scale network. Notably, the shared cluster of reduced volume showed functional integration within the mesocorticolimbic/reward and default mode networks, with neurochemical fingerprinting revealing robust spatial correspondence with dopaminergic, serotonergic, opioid, and endocannabinoid receptor/transporter maps. Overall, these findings suggest that chronic pain and PTSD, beyond disorder-specific alterations, converge on a shared large-scale network organization. The overlap between chronic pain and a prototypical stress-related disorder at the network level provides neurobiological support for conceptualizing chronic pain within a stress-related framework.
]]></description>
<dc:creator><![CDATA[ Li, M., Hou, Y., Liu, D., Zhou, Y., Bore, M. C., Lei, J., Wang, J., Tsang, M. H., Maes, M., Kendrick, K. M., Becker, B., ferraro, s. ]]></dc:creator>
<dc:date>2026-01-22</dc:date>
<dc:identifier>doi:10.64898/2026.01.21.26344503</dc:identifier>
<dc:title><![CDATA[Chronic pain: transdiagnostic meta-analytic evidence of convergent network signature with PTSD]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-22</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.16.26344114v1?rss=1">
<title>
<![CDATA[
Modulation of Posterior Insula Selectively Enhances Nociceptive Sensory Gating in Humans 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.16.26344114v1?rss=1
</link>
<description><![CDATA[
Sensory gating -- the brains ability to filter out repetitive sensory input -- is essential for preventing sensory overload. Impaired gating is frequently observed in nociplastic and other chronic overlapping pain conditions, yet the specific brain regions supporting this inhibitory process in humans remains unclear. Neuroimaging studies examining pain processing implicate the anterior insula (AI), posterior insula (PI), and anterior mid-cingulate cortex (aMCC), but their deeper locations limit direct mechanistic testing using conventional non-invasive techniques. Here, we leveraged low-intensity focused ultrasound (LIFU), a novel non-invasive neuromodulation method with high depth-penetration and millimeter resolution, to examine the contributions of the AI, PI, and aMCC to sensory gating of nociceptive stimuli. Twelve healthy adults completed four counterbalanced visits of a paired-pulse contact heat evoked potential (CHEP) paradigm while receiving LIFU targeted to each region or an active sham. Using surface electroencephalography (EEG), placed at site Cz, we quantified the peak-to-peak (P2P) amplitude of the cortical response to the first stimulus (S1), the second stimulus (S2), and used the ratio of the response to each stimulus (S2/S1 ratio) as an index of sensory gating. Subjective ratings of pain intensity to the second stimulus were also recorded. Results demonstrated that all subjects displayed sensory gating at baseline and thatLIFU produced region-specific effects. Both PI and aMCC neuromodulation reduced subjective pain ratings and significantly decreased S2 amplitude relative to sham, whereas LIFU to AI had no effect. Critically, only PI neuromodulation enhanced sensory gating by reducing the S2/S1 ratio. These findings identify the PI as a key contributor to gating of repetitive nociceptive input and a promising neuromodulation target for remediating sensory gating deficits in nociplastic pain.
]]></description>
<dc:creator><![CDATA[ Isaac, G., Kapoor, A., Strohman, A., Legon, W. ]]></dc:creator>
<dc:date>2026-01-17</dc:date>
<dc:identifier>doi:10.64898/2026.01.16.26344114</dc:identifier>
<dc:title><![CDATA[Modulation of Posterior Insula Selectively Enhances Nociceptive Sensory Gating in Humans]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-17</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.14.26344090v1?rss=1">
<title>
<![CDATA[
A systematic review with Bayesian modelling of the prevalence of pain with neuropathic characteristics 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.14.26344090v1?rss=1
</link>
<description><![CDATA[
We performed the first systematic review and meta-analysis of the prevalence of pain with neuropathic characteristics using Bayesian methods to correct prevalence estimates for the use of screening tools with imperfect sensitivity and specificity (CRD42023416845). We searched major databases for national or regional epidemiological studies that reported the prevalence of pain with neuropathic characteristics, as identified by the PainDETECT, S-LANSS, or DN4-interview. Of the 1,251 unique records retrieved, 8 were finally extracted. The uncorrected (apparent) prevalence data were pooled using a random-effects meta-analysis for proportions. The corrected (true) prevalence was estimated using Bayesian models incorporating sensitivity and specificity distributions under non-informative [beta(1,1)] and informative priors [beta(4.389, 29.522); based on apparent prevalence]. Using the mean values from Bayesian credible intervals, a pooled estimate of true prevalence was generated using a random-effects model. The pooled estimate for the apparent prevalence was 10.6% (95% CI: 8.5; 12.9). The pooled estimate for true prevalence was 4.9% (95% CI: 3.8; 6.1) using informative priors, and 2.3% (95% CI: 1.5; 3.2) using non-informative priors. The use of imperfect screening tools may have overestimated the prevalence of neuropathic pain.

PerspectiveThe prevalence of neuropathic pain may be lower than previously estimated. A lower prevalence should not be equated with reduced societal or clinical significance, but it may have implications for healthcare resource allocation and research funding policies for neuropathic pain.
]]></description>
<dc:creator><![CDATA[ Kamerman, P. R., Hoosen, T., Mnguni, N., Chikezie, P. C. ]]></dc:creator>
<dc:date>2026-01-15</dc:date>
<dc:identifier>doi:10.64898/2026.01.14.26344090</dc:identifier>
<dc:title><![CDATA[A systematic review with Bayesian modelling of the prevalence of pain with neuropathic characteristics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.08.26343598v1?rss=1">
<title>
<![CDATA[
One in seven has severe pain: A point-prevalence study of hospitalised people across Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.08.26343598v1?rss=1
</link>
<description><![CDATA[
Acute pain in hospitalised patients is common and is associated with adverse outcomes, yet African data are scarce. We conducted an international prospective point-prevalence study of adult inpatients across Africa to determine pain prevalence and severity, and explored associations with critical illness and survival status. On a single day, investigators assessed patients worst pain in the preceding 24 hours using a 0-10 visual-numerical scale and recorded vital signs. Critical illness was defined as [&ge;]1 vital sign out of range, according to predefined definitions. Survival was assessed at day 7. Data are presented as median [IQR], n (%), and odds ratios with 95% confidence intervals. Between September and December 2023, 19438 patients from 180 hospitals in 22 African nations were included (age 40 [29; 59] years; 56% female). 67.9% of patients reported pain, with 2795 patients reporting severe pain (pain of [&ge;]7/10). Pain severity did not differ significantly by sex overall, but females [&le;]40 years old, with hypertension or cancer, admitted for trauma or infection, or in surgical wards had higher mean pain ranks than males. Severe pain odds decreased by 11% per standard deviation increase in age. Patients with severe pain had greater odds of critical illness and death within seven days. These findings provide the first large-scale evidence of acute pain burden in African hospitals. Pain is highly prevalent, with one in seven patients reporting severe pain. Future research of effective and feasible strategies to manage acute pain and reduce pain-related adverse clinical outcomes is needed in Africa.
]]></description>
<dc:creator><![CDATA[ Bedwell, G. J., Parker, R., Madden, V. J., Scribante, J., Elhadi, M., Ademuyiwa, A. O., Osinaike, B., Owoo, C., Sottie, D., Khalid, K., Hewitt-Smith, A., Kwizera, A., Belachew, F. K., Mengistu, D. D., Firissa, Y. B., Gemechu, T. B., Dausab, G., Kauta, U., Sikuvi, K., Kechiche, N., Bertille Ki, K., Mukenga, M., Munlemvo, D., Bittaye, M., Jagne, A., Omar, M. A., Daoud, H. A., Faisal, M., Elfiky, M., Seleke, M., Fadalla, T., Koko, A., Bedada, A. G., Outsouta, G. N., Elombila, M., El Adib, A. R., Essafti, M., Lopes, D., Morais, A., Ndarukwa, P., Handireketi, N., Bulamba, F., Mrara, B., Kluyts, H.- ]]></dc:creator>
<dc:date>2026-01-08</dc:date>
<dc:identifier>doi:10.64898/2026.01.08.26343598</dc:identifier>
<dc:title><![CDATA[One in seven has severe pain: A point-prevalence study of hospitalised people across Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.06.26343556v1?rss=1">
<title>
<![CDATA[
Support needs, support use and perceived helpfulness of support in a cohort of people bereaved during the COVID-19 pandemic: Insights from a longitudinal survey 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.06.26343556v1?rss=1
</link>
<description><![CDATA[
BackgroundThe negative impacts of the COVID-19 pandemic on bereavement experiences and grief outcomes are relatively well documented. However, less is known about the evolving support needs of people bereaved during this time, what support they used and, crucially, how this support helped (or hindered) their coping. Beyond the pandemic context, evidence of how bereavement support needs relate to the use and perceived helpfulness of different types of support is needed to inform bereavement service provision and policies.

MethodsA longitudinal survey of people bereaved (any cause of death) during the COVID-19 pandemic in the UK, with data collected at four time points: baseline (T1; n = 711), c. 8 (T2; n = 384), 13 (T3; n = 295), and 25 (T4; n = 185) months post-bereavement. Support needs and use of informal and formal support sources were captured quantitatively at all time points, with the perceived helpfulness of support captured as free-text data and analysed thematically. Future support preferences were obtained in the final survey round (T4). At T2-T4, participants completed the Traumatic Grief Inventory (TGI-SR) to assess for indications of Prolonged Grief Disorder (PGD). Quantitative data were analysed descriptively.

ResultsIn early bereavement, findings demonstrate high levels of support needs across multiple domains, with the highest needs at baseline relating to managing grief and feelings surrounding the loss (49.9-59.8% across 4 items), feelings of anxiety and depression (52.8%) and social isolation and loneliness (52.0%). Support needs decreased markedly over time but persisted for those with indicated PGD, of whom 44.2% at two-years post-bereavement (T4) needed help with coming to terms with how their loved one died and with expressing their feelings and feeling understood and 41.2% with loneliness and isolation. Participants primarily relied on support from family and friends, followed by online community support and one-to-one support (counselling), with support use decreasing over time. Those with indicated PGD engaged with all types of support more frequently across all time points, yet a third (35.3%) did not access any formal bereavement or mental health support during the first year following their bereavement. The qualitatively described benefits of different informal and formal support sources reflected and demonstrated their efficacy in meeting these support needs, though inadequacies in support were also highlighted, particularly from friends and family. Support preferences for future bereavements under non-pandemic circumstances most commonly included family and friends (96%), in-person one-to-one support (75%), self-help resources (63%) and GPs (61%).

ConclusionFindings illustrate the multiple and varied emotional and social support needs of bereaved people, which for those with indicated PGD endured over time. While these needs can be effectively met by informal and formal support-types, dissatisfaction with support from friends and family, and under-utilisation of formal support services amongst high-risk groups, suggests significant unmet need and missed opportunities. This highlights the importance of strengthening the support available to people within their networks and communities and improving access to a wide variety of support options, according to peoples needs and preferences.
]]></description>
<dc:creator><![CDATA[ Goss, S., Barawi, K., Sutton, E., Oates, R., Seddon, K., Sivell, S., Longo, M., Penny, A., Selman, L. E., Harrop, E. ]]></dc:creator>
<dc:date>2026-01-08</dc:date>
<dc:identifier>doi:10.64898/2026.01.06.26343556</dc:identifier>
<dc:title><![CDATA[Support needs, support use and perceived helpfulness of support in a cohort of people bereaved during the COVID-19 pandemic: Insights from a longitudinal survey]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-08</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.03.26343375v1?rss=1">
<title>
<![CDATA[
TRANSLATION AND VALIDATION OF A SPANISH PRELIMINARY VERSION OF THE PACKA QUESTIONNAIRE AMONG PATIENTS WITH FIBROMYALGIA 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.03.26343375v1?rss=1
</link>
<description><![CDATA[
BackgroundPatients understanding of pain and its biopsychosocial nature is thought to be important in order to optimize treatment decisions and treatment outcomes. A validated Spanish questionnaire for patients based on a biopsychosocial model assessing knowledge and attitudes of pain was unavailable. The aim of this study is to validate the Spanish version of the PACKA, to have a Spanish questionnaire to be used among pain patients in both clinical and research settings.

MethodsPhase 1: forward and backward translation, and expert committee; Phase 2: a cross-sectional and longitudinal study among Fibromyalgia patients. In the cross-sectional study (n =330), internal consistency, structural validity and hypothesis testing were examined.

ResultsThe 26-item PACKA was translated and validated in 4 stages. Acceptable internal consistency and test-retest reliability was demonstrated. Internal consistency: Cronbachs  =0.776. Hypotheses testing: associations with the Neurophysiology of Pain Questionnaire r =0.31.

ConclusionThis Spanish version of PACKA has shown acceptable validity and reliability in patients with Fibromyalgia. Further use and reanalysis of the questionnaire might improve this preliminary validation.
]]></description>
<dc:creator><![CDATA[ Albajes, K., Serrat, M., Feliu-Soler, A., Moseley, L., Almirall, M., Reezigt, R. ]]></dc:creator>
<dc:date>2026-01-04</dc:date>
<dc:identifier>doi:10.64898/2026.01.03.26343375</dc:identifier>
<dc:title><![CDATA[TRANSLATION AND VALIDATION OF A SPANISH PRELIMINARY VERSION OF THE PACKA QUESTIONNAIRE AMONG PATIENTS WITH FIBROMYALGIA]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-04</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.02.26343333v1?rss=1">
<title>
<![CDATA[
"I need policymakers to listen": a stakeholder needs assessment concerning anticipatory injectable medication systems, using a novel qualitative survey 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.02.26343333v1?rss=1
</link>
<description><![CDATA[
BackgroundAnticipatory injectable medications for symptom control are a key end-of-life care intervention. However, ensuring their safe and timely use in the community is a global challenge. The needs and priorities of stakeholders involved in processes for prescribing and administering these medications remain underexplored. We must understand these perspectives to design inclusive and adaptive systems.

AimTo identify the needs and priorities of key stakeholders involved in community-based systems for using anticipatory injectable medications.

DesignWe adopted a qualitative exploratory design, using an online survey between September and October 2024. Participants provided anonymised demographic information and completed up to four prompts capturing their stakeholder role, needs and priorities. Data were analysed using a combined inductive-deductive framework to produce synthesised shortlists of priorities and needs.

Setting/participantsUK-based professional and public participants were recruited through social media, professional networks, charities, and public engagement events.

ResultsIn total, 439 participants contributed 729 responses across various stakeholder groups. Findings revealed substantial diversity in stakeholder needs and priorities, both within and between groups. However, most stakeholder groups prioritised timely care, minimising of suffering, and wanted nationally consistent guidance for using injectable medications. Broader societal influences also shaped responses.

ConclusionsOur findings highlight wide diversity in priorities and needs between stakeholders for using anticipatory injectable medications in the community. We propose that inclusive system design should include comprehensive assessment of key stakeholders needs and priorities, with the aim of providing better care. Our study demonstrates that stakeholder needs assessment offers a valuable framework to achieve this.

What is already known about the topic?O_LIAnticipatory injectable medications are a widely used intervention in several countries to support timely end-of-life symptom control at home.
C_LIO_LIThere are ongoing challenges with delays, inconsistent access, and variations in prescribing and governance across regions, indicating that system design influences both timeliness and safety.
C_LIO_LIExisting research has primarily focused on the needs of individual professional groups, and no prior work has mapped the differing needs of all stakeholders involved in these systems.
C_LI

What this paper adds?O_LIOur study demonstrates that stakeholder groups have diverse needs but most share some core priorities -timely care, national consistency in practice guidance, and minimising suffering.
C_LIO_LIWider societal factors and concerns shape stakeholder expectations of end-of-life medication systems.
C_LIO_LIOur approach to stakeholder needs assessment reveals system requirements that consensus-based or single-perspective approaches often overlook.
C_LI

Implications for practice, theory, or policyO_LISystem improvements should be tailored to the specific needs of key stakeholder groups rather than assuming uniform priorities.
C_LIO_LIStrong cross-stakeholder support exists for national, practical guidance on anticipatory prescribing, equipment, training, and governance.
C_LIO_LIStakeholder needs assessment offers a useful method for designing safer, more responsive end-of-life medication systems.
C_LI
]]></description>
<dc:creator><![CDATA[ Perera, B., Bowers, B. ]]></dc:creator>
<dc:date>2026-01-03</dc:date>
<dc:identifier>doi:10.64898/2026.01.02.26343333</dc:identifier>
<dc:title><![CDATA["I need policymakers to listen": a stakeholder needs assessment concerning anticipatory injectable medication systems, using a novel qualitative survey]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.01.02.26343350v1?rss=1">
<title>
<![CDATA[
An external, contemporary evaluation of the Epic End of Life Care Index among hospitalized patients across two large health systems: A retrospective cohort study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.01.02.26343350v1?rss=1
</link>
<description><![CDATA[
BackgroundThe Epic End of Life Care Index (EOLCI) predicts one-year mortality and was developed to improve serious illness care. However, prior external EOLCI evaluations had limited sample sizes, populations, and equity evaluations. In preparation for a multi-system pragmatic clinical trial, we sought to evaluate the EOLCI performance and equity in the trials two participating health systems.

ObjectiveEvaluate EOLCI model performance overall and across key subgroups.

Design/Setting/PatientsRetrospective cohort study of patients hospitalized for [&ge;]36 hours in 2022 to 39 hospitals in the Trinity Health and Kaiser Permanente Southern California (KPSC) health systems.

MeasurementsWe predicted one-year mortality risk stratified by health system using the EOLCI, a logistic regression model including age, sex, race/ethnicity, ethnicity, insurance, and diagnoses. We evaluated model performance using Scaled Brier Scores (SBS; range -1 to 1; composite measures of calibration and discrimination), calibration plots, and c-statistics.

ResultsAmong 116,749 Trinity patients with 154,063 encounters, 12,054 (10.3%) patients died within one year. Among 94,489 KPSC patients with 133,043 encounters, 16,872 (17.9%) died within one year. The SBS was -0.007 at Trinity and 0.178 at KPSC. Calibration was poor for both. Trinitys discrimination was acceptable/good (c-statistic 0.76, 95% CI 0.76-0.77), and KPSCs was good/very good (c-statistic 0.81, 95% CI 0.81-0.81). Model performance across subgroups was similar to the overall cohort.

LimitationsDeath data were collected exclusively within Trinity and KPSC, risking outcome misclassification; several subgroup evaluations were limited by small sample sizes.

ConclusionsAn external evaluation of the widely available Epic EOLCI demonstrated adequate to very good discrimination, poor calibration, and equitable performance across sociodemographic characteristics and diagnoses in two of the nations largest health systems.

Primary funding sourcePCORI PLACER-2022C3-30553.
]]></description>
<dc:creator><![CDATA[ Kohn, R., Courtright, K. R., Grau-Sepulveda, M., Olsen, M. K., Madden, V. L., Sewell, B., Sheu, D., Ahmad, Y. S., Auriemma, C. L., Nimetz, A., Dennos, A., Hart, K. W., Lee, J., Creekmur, B., Nau, C. L., Nguyen, H. Q., Wang, S., Boyer, G., Lundstrom, T., Postema, L., Roth, D. J., Vandewarker, J., Halpern, S. D., Lokhnygina, Y. ]]></dc:creator>
<dc:date>2026-01-03</dc:date>
<dc:identifier>doi:10.64898/2026.01.02.26343350</dc:identifier>
<dc:title><![CDATA[An external, contemporary evaluation of the Epic End of Life Care Index among hospitalized patients across two large health systems: A retrospective cohort study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-03</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.31.25343260v1?rss=1">
<title>
<![CDATA[
Higher pre-treatment evoked alpha-band oscillatory brain dynamics predict chronic pain reduction of non-invasive brain stimulation of non-motor targets 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.31.25343260v1?rss=1
</link>
<description><![CDATA[
Repetitive transcranial magnetic stimulation (rTMS) of non-motor cortical targets, including the left dorsolateral prefrontal cortex (DLPFC), anterior cingulate cortex (ACC), and posterosuperior insula (PSI), has been proposed as a treatment for chronic pain with variable clinical outcomes. Pre-treatment local cortical dynamics were hypothesized to serve as markers of chronic pain reduction. In this secondary analysis of a large clinical trial comparing different rTMS targets for pain relief, it was examined whether pre-treatment evoked cortical responses measured by electroencephalography after TMS of DLPFC, ACC, or PSI were associated with at least 30 percent reduction in pain intensity scored on a visual analogue scale. Forty-five patients with chronic pain received 12 sessions over eight weeks of 10 Hz rTMS to DLPFC, ACC or PSI. Cortical reactivity was quantified using global and local mean field power, and oscillatory dynamics were assessed using event-related spectral perturbation (ERSP) and inter-trial coherence (ITC) in the alpha-band (8-12 Hz). Responders (20 of 45, 44%) compared with non-responders showed higher pre-treatment alpha-band ERSP and ITC over the stimulated cortical targets (both P<0.05), and higher alpha-band ERSP and ITC values were negatively correlated with the percentage change in pain intensity (both P < 0.05). These results suggest that elevated pre-treatment TMS-evoked alpha-band oscillatory activity may indicate a higher probability of pain reduction to non-motor rTMS in chronic pain. This supports the development of enrichment strategies using cortical neurophysiology-based markers in neuromodulation trials aimed at individualized, precision-oriented treatments.
]]></description>
<dc:creator><![CDATA[ De Martino, E., Bach, M. M., Couto, B. N., Jakobsen, A., Ingemann-Molden, S., Casali, A., Graven-Nielsen, T., Ciampi de Andrade, D. ]]></dc:creator>
<dc:date>2026-01-02</dc:date>
<dc:identifier>doi:10.64898/2025.12.31.25343260</dc:identifier>
<dc:title><![CDATA[Higher pre-treatment evoked alpha-band oscillatory brain dynamics predict chronic pain reduction of non-invasive brain stimulation of non-motor targets]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-02</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.24.25342351v1?rss=1">
<title>
<![CDATA[
Genome Wide Association Analysis of Two Pore Domain Potassium Channel Gene Regions Reveals Multiple Pain-Associated Signals 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.24.25342351v1?rss=1
</link>
<description><![CDATA[
Two-pore domain potassium (K2P) channels are novel analgesic drug targets with existing in vitro and in vivo validation, however genetic associations in large scale populations have not been widely reported. By examining two comprehensive genetic databases (UK Biobank & FinnGen) and 136 pain-related traits, we highlight that multiple pain-associated signals are present within 500 kb of K2P gene transcripts, with particularly strong evidence for KCNK5 (TASK-2) and headache-related traits. This data benchmarks remarkably well against gene targets already considered to be well validated pain targets (voltage-gated sodium and transient receptor potential channels) and is enhanced when examining populations regularly consuming analgesics who also report pain. This data supports a rationale for developing therapeutic strategies to modulate K2P function in patient populations experiencing pain.
]]></description>
<dc:creator><![CDATA[ Bourne, S. R., Cook, J., Wright, P. D., Jerman, J., Forfar, R., Veale, E. L., Mathie, A. ]]></dc:creator>
<dc:date>2026-01-01</dc:date>
<dc:identifier>doi:10.64898/2025.12.24.25342351</dc:identifier>
<dc:title><![CDATA[Genome Wide Association Analysis of Two Pore Domain Potassium Channel Gene Regions Reveals Multiple Pain-Associated Signals]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2026-01-01</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.11.25341892v1?rss=1">
<title>
<![CDATA[
How do general practitioners consider health literacy in pain medication treatment of patients suffering from chronic musculoskeletal pain? a mixed methods study. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.11.25341892v1?rss=1
</link>
<description><![CDATA[
BackgroundHealth literacy (HL) influences communication quality, treatment adherence, and equity in care. However, how general practitioners (GPs) recognize and respond to patients HL in everyday clinical reasoning remains insufficiently understood.

ObjectiveTo investigate how Danish GPs incorporate patients health literacy into decisions about prescribing pain medication for chronic musculoskeletal pain, using insights from surveys, interviews, and a literature review.

MethodsA mixed-methods design combined survey data from 39 Danish GPs, seven qualitative interviews, and a synthesis of 14 studies on HL in general practice. The literature was used to contextualize and contrast the empirical findings. Quantitative data were analyzed descriptively, while qualitative data underwent thematic analysis. All three datasets were integrated through mixed-methods comparison to assess convergence, divergence, and complementarity.

ResultsAcross the integrated survey, interview, and literature findings, HL emerged as a largely implicit but consistent element of GP decision-making. In the Danish survey and interview data, some GPs explicitly reported considering HL in prescribing decisions, yet interviews showed that HL more often influenced clinical reasoning indirectly through intuition and conversation. GPs adapted communication, explanations, and treatment planning to their perceptions of patient understanding, but these adjustments were rarely guided by structured tools or frameworks. Conversation appeared as the main approach for assessing comprehension, echoing patterns observed in the literature. Many Danish GPs perceived most patients as competent and self-managing, a perception the literature cautions may mask hidden comprehension challenges. Finally, both local interviews and existing studies highlighted digital HL as an emerging theme, with GPs commonly managing patients online health information through conversational reframing rather than formal strategies.

ConclusionsHL is tacitly integrated into GP reasoning but remains under-recognized as a professional skill. Making HL an explicit component of communication training, reflective practice, and prescribing guidelines could improve patient understanding, shared decision-making, and treatment equity.
]]></description>
<dc:creator><![CDATA[ Nielsen, R. B., Lyng, K. D., Andreucci, A., Olesen, A. E., Nielsen, R. O., Kallestrup, P., Rathleff, M. S. ]]></dc:creator>
<dc:date>2025-12-18</dc:date>
<dc:identifier>doi:10.64898/2025.12.11.25341892</dc:identifier>
<dc:title><![CDATA[How do general practitioners consider health literacy in pain medication treatment of patients suffering from chronic musculoskeletal pain? a mixed methods study.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2025-12-18</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.11.25342089v1?rss=1">
<title>
<![CDATA[
Integrating physiotherapy into social prescribing pathways for chronic pain management 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.11.25342089v1?rss=1
</link>
<description><![CDATA[
BackgroundChronic pain affects 28 million UK adults. While physiotherapy and social prescribing are recognised as effective, evidence on integrating them remains limited. Digital biomarkers could objectively assess movement quality and pain physiology to support clinical decision-making.

ObjectivesTo explore whether simple kinematic and electroencephalography (EEG) biomarkers can discriminate between correct versus incorrect exercise performance and high versus low pain states, and to consider how such tools might streamline social prescribing pathways for chronic pain.

MethodsSecondary analyses of two open datasets: (1) KERAAL kinematic dataset: 900 recordings of trunk rotation exercises (21 participants) labelled "correct" or "incorrect" by physiotherapists; (2) EEG dataset: 145 resting-state recordings (100 individuals with chronic pain) categorised as high or low pain. Classification models (logistic regression, support vector machines, gradient boosting) were trained on extracted kinematic features (range of motion, smoothness, symmetry, jerk, coordination) and EEG features (frontal alpha asymmetry, connectivity, sample entropy, aperiodic exponents). Performance was assessed using accuracy, F1 score, AUC and calibration curves.

ResultsKinematic classification achieved near-perfect performance: 100% accuracy and AUC = 1.00. Key features were shoulder abduction peak angle, symmetry index and jerk. EEG classification was strong: 93% accuracy, 0.97 AUC. Global theta and alpha connectivity, frontal alpha asymmetry and sample entropy were most informative.

ConclusionAutomated kinematic and EEG markers can reliably differentiate correct exercise performance and current pain state. These digital biomarkers could inform physiotherapists and link workers when triaging patients into social prescribing programmes. Integrating digital assessment into social prescribing may reduce unnecessary appointments, enhance self-management and align care with the biopsychosocial model. Further studies should validate the approach in broader populations and examine implementation in real-world social prescribing services.
]]></description>
<dc:creator><![CDATA[ Syed, A. U. ]]></dc:creator>
<dc:date>2025-12-15</dc:date>
<dc:identifier>doi:10.64898/2025.12.11.25342089</dc:identifier>
<dc:title><![CDATA[Integrating physiotherapy into social prescribing pathways for chronic pain management]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2025-12-15</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.04.25341572v1?rss=1">
<title>
<![CDATA[
Effects of childhood adversity on socially learned placebo analgesia in virtual reality: A cross-sectional study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.04.25341572v1?rss=1
</link>
<description><![CDATA[
Early life adversity (ELA), indexed through Adverse Childhood Experiences (ACEs), is associated with long-term alterations in emotion regulation, stress responsivity, and social learning--factors that may shape learned pain modulation. Social observation in immersive virtual environments offers a powerful way to investigate these mechanisms.

To examine whether ELA influences social observation-induced placebo analgesia and empathy responses in immersive and non-immersive contexts.

Adults with self-reported low versus high ACE exposure completed an observational learning task in immersive virtual reality (VR) or a non-immersive format. Participants observed Human or Avatar demonstrators experiencing pain relief and then underwent self-pain testing. Measures included socially induced placebo analgesia and affective and cognitive components of state empathy.

Individuals with high ACE exposure showed stronger social observation-induced placebo analgesia, particularly within immersive VR. High ACE participants exhibited reduced affective state empathy, while cognitive empathy remained comparable to the low ACE group.

Elevated ELA is unexpectedly associated with enhanced responsiveness to socially learned placebo analgesia, especially in immersive VR settings. These findings highlight how early adversity may shape sensitivity to socially transmitted treatment cues, with implications for the design of VR-based therapeutic interventions.
]]></description>
<dc:creator><![CDATA[ Watson, L., Wang, Y., White, J. N., Shafir, R., Colloca, G., Heagerty, J., Li, S., Brawn, B., Varshney, A., Chen, S., Colloca, L. ]]></dc:creator>
<dc:date>2025-12-09</dc:date>
<dc:identifier>doi:10.64898/2025.12.04.25341572</dc:identifier>
<dc:title><![CDATA[Effects of childhood adversity on socially learned placebo analgesia in virtual reality: A cross-sectional study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2025-12-09</prism:publicationDate>
<prism:section></prism:section>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2025.12.05.25341696v1?rss=1">
<title>
<![CDATA[
Peripheral magnetic stimulation of the upper-limb nerves: evoked sensations, phantom-pain relief, and cortical responses 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2025.12.05.25341696v1?rss=1
</link>
<description><![CDATA[
Peripheral magnetic stimulation (PMS) is a noninvasive technique applicable to post-stroke rehabilitation, treatment of phantom limb pain (PLP) and generating neuroprosthetic sensations. Here we aimed to test whether PMS could be utilized to enable sensory feedback from hand prostheses and suppress PLP. Accordingly, we induced somatic sensations with PMS and conducted EEG measurements to assess sensory evoked potentials (SEPs) in 30 able-bodied participants (controls) and 11 individuals with transradial amputation. Single PMS pulses of varying amplitude were applied to the left arm locations overlying the median, radial, and ulnar nerves. Subjective accounts of sensations were collected using PerceptMapper, the University of Pittsburghs multitouch interface. After the best location for PMS was found, continuous stimulation (20 or 40 Hz, delivered in 5-min blocks with 5-7 min interblock intervals for patricipant breaks and EEG setup checks) was applied. The control participants reported experiencing sensations in their hands. The amputees felt sensations in their phantom hands. PMS evoked SEPs in both the controls and amputees. The analysis of intertrial coherence showed significant phase consistency of the stimulus-locked EEG responses across trials for the controls and amputees. The measurements of visual analogue scale (VAS) scale showed that PMS did not change PLP in 2 participants, increased it in 4, and decreased in 3. We propose that PMS could be used to assess the effects of peripheral nerve stimulation on somatic sensations, PLP and cortical activity prior to the surgical placement of electrode implants.

Significance StatementPeople with amputation have two critical needs: (1) their prosthetic limbs being augmented with naturalistic somatic sensations, and (2) their PLP, which develops in the majority of cases, being suppressed. Electrical stimulation with peripheral nerve implants offers a solution for both needs, but invasiveness of this procedure poses a number of problems. Here we show that PMS offers a noninvasive tool for testing the effects of peripheral nerve stimulation before any invasive implants are placed. PMS causes somatic sensations, modulates PLP and evokes cortical responses evident in EEG recordings. These effects of PMS were documented in both healthy controls and amputees. The results suggest that PMS combined with EEG measurements could serve as tools for testing potential implantation sites.
]]></description>
<dc:creator><![CDATA[ Grigoreva, O., Samsonov, T., Dolgoarshinnaia, A., Lebedev, M., Soghoyan, G. ]]></dc:creator>
<dc:date>2025-12-05</dc:date>
<dc:identifier>doi:10.64898/2025.12.05.25341696</dc:identifier>
<dc:title><![CDATA[Peripheral magnetic stimulation of the upper-limb nerves: evoked sensations, phantom-pain relief, and cortical responses]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory</dc:publisher>
<prism:publicationDate>2025-12-05</prism:publicationDate>
<prism:section></prism:section>
</item>
</rdf:RDF>
